BioFire Diagnostics Inc. has raised $25 million in new funding from New York-based Athyrium Opportunities Fund. The money will be used to help commercialize the company’s “FilmArray” diagnostic ...

SALT LAKE CITY--(BUSINESS WIRE)--BioFire Diagnostics, Inc., today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,394,608 covering the company’s FilmArray ...

MARCY L’ÉTOILE, France--(BUSINESS WIRE)-- Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary ...

PARIS, Sept 4 (Reuters) - French biotech firm BioMerieux will buy privately-owned U.S. rival BioFire Diagnostics for $450 million, in a deal aimed at consolidating its position as a major player in ...

SALT LAKE CITY, May 2, 2013 /PRNewswire/ -- BioFire Diagnostics, Inc. today announced the expansion of its financing commitment with Athyrium Opportunities Fund to $45 million from $25 million. The ...

SALT LAKE CITY, Utah (March 26, 2013) — BioFire Diagnostics, Inc. today announced that it has signed a competitive prototyping contract with the Department of the Army for Increment 1 of the Next ...

MARCY-L'ÉTOILE, France, April 9, 2026 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, announces the launch of BIOFIRE ® SPOTFIRE ® for pharmaceutical industries, where ...

BioFire Diagnostics won 510(k) clearance for its gastrointestinal panel for infectious diarrhea, following in the footsteps of the company's acquisition by French diagnostic giant bioMérieux.

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

Article ‘Count’ and ‘Share’ for BioFire Diagnostics based on listed parameters only. According to the parameters selected above, there are no articles from BioFire Diagnostics from 1 September 2024 - ...